FY2025 EPS Estimates for Tilray Lifted by Atb Cap Markets

Tilray Inc (NASDAQ:TLRY) – Equities research analysts at Atb Cap Markets raised their FY2025 earnings estimates for shares of Tilray in a note issued to investors on Monday, December 16th. Atb Cap Markets analyst F. Gomes now expects that the company will post earnings of ($0.13) per share for the year, up from their previous forecast of ($0.14). The consensus estimate for Tilray’s current full-year earnings is ($0.14) per share. Atb Cap Markets also issued estimates for Tilray’s FY2026 earnings at ($0.11) EPS, FY2027 earnings at ($0.04) EPS and FY2029 earnings at $0.05 EPS.

Separately, Roth Mkm reduced their price target on shares of Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a research report on Friday, October 11th.

Tilray Price Performance

Tilray stock opened at $1.16 on Thursday. The firm has a market capitalization of $1.05 billion, a P/E ratio of -4.30 and a beta of 2.08. The business has a 50-day moving average of $1.45 and a 200-day moving average of $1.66. The company has a current ratio of 2.47, a quick ratio of 1.57 and a debt-to-equity ratio of 0.08. Tilray has a 1 year low of $1.15 and a 1 year high of $2.97.

Tilray (NASDAQ:TLRY) last announced its quarterly earnings data on Thursday, October 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The firm had revenue of $200.00 million for the quarter, compared to analysts’ expectations of $218.70 million. During the same period last year, the firm earned ($0.10) earnings per share. The business’s revenue for the quarter was up 13.0% on a year-over-year basis.

Insider Activity at Tilray

In other news, CFO Carl A. Merton bought 26,000 shares of the stock in a transaction on Friday, November 15th. The stock was purchased at an average price of $1.36 per share, for a total transaction of $35,360.00. Following the acquisition, the chief financial officer now owns 26,000 shares in the company, valued at approximately $35,360. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.87% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Synovus Financial Corp lifted its stake in Tilray by 176.7% in the 3rd quarter. Synovus Financial Corp now owns 36,092 shares of the company’s stock valued at $64,000 after acquiring an additional 23,046 shares in the last quarter. Barclays PLC raised its holdings in shares of Tilray by 600.4% in the third quarter. Barclays PLC now owns 204,144 shares of the company’s stock valued at $359,000 after purchasing an additional 174,997 shares during the last quarter. Toronto Dominion Bank lifted its position in shares of Tilray by 454.5% in the third quarter. Toronto Dominion Bank now owns 128,923 shares of the company’s stock worth $227,000 after purchasing an additional 105,671 shares in the last quarter. XTX Topco Ltd boosted its holdings in Tilray by 1,079.7% during the third quarter. XTX Topco Ltd now owns 281,504 shares of the company’s stock worth $495,000 after purchasing an additional 257,641 shares during the last quarter. Finally, State Street Corp grew its position in Tilray by 4.7% in the third quarter. State Street Corp now owns 1,961,338 shares of the company’s stock valued at $3,452,000 after purchasing an additional 88,079 shares in the last quarter. 9.35% of the stock is owned by institutional investors and hedge funds.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.